

BREAKING NEWS**Lakhimpur Kheri case: Supreme Court expresses unhappiness over the status report**

Advertisement

BUSINESS

Advertisement

Updated on: Friday, October 29, 2021, 05:10 PM IST

Dr Reddy's Q2 net profit up 30% to Rs 992 cr on robust sales

Agencies



Dr. Reddy's is conducting clinical trials for Sputnik Light and Molnupiravir and is also developing several other COVID19 drugs for treatment ranging from mild to severe conditions / Representative Image |

Advertisement

RECENT STORIES**FPJ Legal: Drugs on-cruise case witness KP Gosavi's police****'Rise above the noise': Chris Pratt gets support from mother-in-****Mumbai cruise drugs bust case: Independent witness****Parliament Panel suggests Winter Session from November 29 to****Indian ocean region to face complicated security situation**

Advertisement

Dr Reddy's Laboratories on Friday reported a 30 per cent jump in its consolidated net profit to Rs 992 crore for the quarter ended September 30, 2021, on account of robust sales in all markets.

The company had posted a net profit of Rs 762.3 crore for the corresponding period of the previous financial year, Dr Reddy's Laboratories said in a regulatory filing.

—ADVERTISEMENT—





Its consolidated revenue during July-September 2021 stood at Rs 5,763.2 crore. It was Rs 4,896.7 crore in the year-ago period, it added.

"I am pleased with the improvement in the financial performance across our businesses. While we continue to strengthen our core businesses of generics and APIs (active pharmaceutical ingredients), we are also making investments in our long-term growth drivers and deeper innovation capabilities," Dr Reddy's Laboratories Co-Chairman and Managing Director G V Prasad said.

The company's focus remains on meeting unmet patient needs around the world in keeping with its purpose, he added.

"We continue to play our role in the fight against COVID19 by acting proactively to bring multiple preventive and curative treatment options, including a vaccine.

"Our major COVID19 products launched till now include Sputnik V vaccine, Remdesivir, Avigan and 2-deoxy-D-glucose (2-DG). We have commercialised all these products in India and some of the products in overseas markets," Dr Reddy's said.

Currently, Dr Reddy's is conducting clinical trials for Sputnik Li and Molnupiravir, and is also developing several other COVID19 drugs for treatment ranging from mild to severe conditions, it added.

Shares of Dr Reddy's Laboratories were trading at Rs 4,857.70 per scrip on the BSE, up 6.22 per cent from its previous close.

(With inputs from PTI)

(To receive our E-paper on whatsapp daily, please [click here](#). We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Published on: Friday, October 29, 2021, 05:10 PM IST


Advertisement



**Plate Laser Cutting Machine
Working On All Metal**

A series

Inquiry



SHOP NOW



Egypt throws a spatula in Indian Basmati rice exports

BusinessLine | Sponsored

Why India shouldn't sign on to net zero

TheHindu.com | Sponsored

My Daughter Brain Tumor Is Spreading. She'll Die Without Help.

Ketto | Sponsored

Get a free Public Speaking Class for your Child!

Exclusively for Ages 4-14

PlanetSpark | Sponsored

Become A Data Scientist. No Technical Background Required.

Great Learning | Sponsored

30 Heart Disease Warning Signs That You Shouldn't Ignore

Articles Mansion | Sponsored

Attention-These Are Warning Signs Before A Heart Attack

Housediver | Sponsored

Born between 1975-1990? Check eligibility for 2Cr Term Plan

New Max Life Term Plan | Sponsored

The cost of hearing aids in Gautam Buddha Nagar might surprise you

Hear.com | Sponsored

Late Sandalwood actor Puneeth Kumar's doctor gets police protection following threats

[Read Next Story >](#)

Book a free coding class for kids aged 6-18 yrs.

Learn to create games, apps and much more with WhiteHat Jr. Online coding classes for ages 6-18.

WhiteHat Jr | Sponsored

[About Us](#) [Editorial Policy](#) [Careers](#) [Disclaimer](#) [Privacy Policy](#) [Contact Us](#) [Advertise With Us](#) [RSS](#)

Free Press Journal

Follow us on